Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Non-metastatic NSCLC and other thoracic malignancies

2381 - Multiplexed targeted proteomics signature for serum diagnostic of malignant pleural mesothelioma

Date

11 Sep 2017

Session

Non-metastatic NSCLC and other thoracic malignancies

Topics

Translational Research;  Mesothelioma

Presenters

Ferdinando Cerciello

Citation

Annals of Oncology (2017) 28 (suppl_5): v568-v572. 10.1093/annonc/mdx389

Authors

F. Cerciello1, M. Choi2, K. Lomeo1, J.M. Amann1, E. Felley-Bosco3, R.A. Stahel4, B. Robinson5, J. Creaney5, H.I. Pass6, O. Vitek2, D.P. Carbone1

Author affiliations

  • 1 James Thoracic Center, James Cancer Center, The Ohio State University Medical Center, 43210 - Columbus/US
  • 2 College Of Science, College Of Computer And Information Science, Northeastern University, Boston/US
  • 3 Laboratory Of Molecular Oncology, University Hospital Zürich, Zürich/CH
  • 4 Laboratory Of Molecular Oncology, Department Of Oncology, University Hospital Zürich, Zürich/CH
  • 5 National Centre For Asbestos Related Disease, University of Western Australia, School of Medicine and Pharmacology, Nedlands/AU
  • 6 Langone Medical Center, New York University, New York/US
More

Resources

Abstract 2381

Background

Detection of mesothelioma from blood is challenging. Current proposed biomarkers mainly rely on single protein cancer products detected in serum or plasma. Here, we investigate if a mass spectrometry based multiplexed proteomic biomarker signature can improve accuracy of mesothelioma detection in serum.

Methods

We used targeted proteomics technology to investigate more than 400 serum samples from cohorts of mesothelioma and asbestos exposed donors from USA, Australia and Europe. Serum samples were processed for enrichment of N-linked glycoproteins on 96-well plates before peptide separation on ultra performance liquid chromatography (UPLC) followed by targeted analysis on a triple quadrupole type of mass spectrometer. The software Skyline was used for data visualization. Workflow for quantitative large scale data analysis was based on the software package MSstats.

Results

We applied logistic regression models for a multiplexed signature of six peptides from six different proteins, including the biomarker mesothelin. In the receiver operating curve, signature had an area under the curve (AUC) of 0.76 in discriminating mesothelioma from asbestos exposed donors in a training set of 212 donors. AUC in a separated validation set of 193 donors was 0.72. In the validation set, AUC was 0.74 in separating mesothelioma early stages I/II from asbestos exposed. In comparison, single mesothelin peptide assessed by mass spectrometry discriminated mesothelioma from asbestos exposed with AUC of 0.71 in training and AUC of 0.64 in validation set, and mesothelioma early stages I/II were separated from asbestos exposed with AUC of 0.66 in the validation set.

Conclusions

Diagnostic strategies based on multiplexed targeted proteomics biomarkers bear potential of an increased accuracy for detection of mesothelioma in serum.

Clinical trial identification

Legal entity responsible for the study

James Thoracic Center, The Ohio State University Medical Center

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.